Insight

Yakup Ergün: Benefit of systemic therapy in MINDACT patients with small ER+ HER2- Breast Cancer

obdh.com.tr

Nov 3, 2024, 16:08

Yakup Ergün: Benefit of systemic therapy in MINDACT patients with small ER+ HER2- Breast Cancer

Yakup Ergün, Medical Oncologist at Bower Hospital, shared a post on X about a recent paper by Florentine Hilbers et al. published in NPJ Breast Cancer:

“Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative Breast Cancer.

In clinically low-risk (T<1cm, N0) HR+/HER2- patients, there is no benefit of adjuvant chemotherapy in genomically high-risk patients according to MammaPrint.”

“Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers”

Authors: Florentine Hilbers, Coralie Poncet, Konstantinos Tryfonidis, Laura van ’t Veer, Fatima Cardoso et al.

Yakup Ergün: Benefit of systemic therapy in MINDACT patients with small ER+ HER2- Breast Cancer

More posts featuring Yakup Ergün.

Breast Cancer cancer Coralie Poncet ER+/HER2- breast cancer Fatima Cardoso Florentine Hilbers Konstantinos Tryfonidis Laura van ’t Veer MammaPrint MINDACT npj breast cancer OncoDaily Oncology Yakup Ergün

New €4.9m Beaumont RCSI Cancer Centre and Irish Cancer Society Partnership to Transform Lung Cancer Care in Ireland

Biden Cancer Moonshot Initiative Awards Over $6 Million to 11 Early-Career Researchers for Innovative Cancer Research

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Special Coverage